Hikma to buy Ben Venue's Bedford Labs for up to $300m
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals is to buy Bedford Laboratories, the US generic injectables business of Ben Venue Laboratories, which is part of Boehringer Ingelheim. Hikma will pay $225m up front and a further $75m in contingent cash payments if certain performance-related milestones, over a period of five years, are achieved.